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Extensive Disease Small Cell Lung Cancer Dose-Response
Relationships
Implications for Resistance Mechanisms
David J. Stewart, MD, FRCPC,* Constance Johnson, MD, PhD,¶ Adriana Lopez, MS,†
Bonnie Glisson, MD,* Jay M. Rhee, MD,‡ and B. Nebiyou Bekele, PhD†
Background: Some studies (but not others) suggested that high
doses are beneficial in small cell lung cancer (SCLC). We hypoth-
esized that dose-response curve (DRC) shape reflects resistance
mechanisms.
Methods: We reviewed published SCLC clinical trials and con-
verted response rates into estimated mean tumor cell kill, assuming
killing is proportional to reduction in tumor volume. Mean % cell
survival was plotted versus planned dose intensity. Nonlinear and
linear meta-regression analyses (weighted according to the number
of patients in each study) were used to assess DRC characteristics.
Results: Although associations between dose and cell survival were
not statistically significant, DRCs sloped downward for five of seven
agents across all doses and for all seven when lowest doses were
excluded. Maximum mean cell kill across all drugs and doses was
approximately 90%, suggesting that there may be a maximum
achievable tumor cell kill irrespective of number of agents or drug
doses.
Conclusions: Downward DRC slopes suggest that maintaining
relatively high doses may possibly maximize palliation, although the
associations between dose and slope did not achieve statistical
significance, and slopes for most drugs tended to be shallow. DRC
flattening at higher doses would preclude cure and would suggest
that “saturable passive resistance” (deficiency of factors required for
cell killing) limits maximum achievable cell kill. An example of
factors that could flatten the DRC at higher doses and lead to
saturable passive resistance would be presence of quiescent, non-
cycling cells.
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(J Thorac Oncol. 2010;5: 1826–1834)
Chemotherapy with or without radiotherapy for patients withlimited disease (LD) small cell lung cancer (SCLC) has a
5-year survival rate of 10 to 25%.1,2 In extensive disease (ED)
SCLC, chemotherapy gives complete responses in more than
20% of patients and prolongs median survival.1,2 Common
regimens used in SCLC include etoposide-cisplatin (EP) and
cyclophosphamide-doxorubicin-vincristine (CAV). Carboplatin,
ifosfamide, epirubicin, paclitaxel, vinorelbine, topotecan, irino-
tecan, gemcitabine, pemetrexed, and other agents may also be
used.1–5 Patients with prior responses often benefit from further
chemotherapy if progression occurs more than 3 months after
completing prior chemotherapy (“sensitive relapse”), whereas
they will generally be resistant to further chemotherapy if pro-
gression occurs during or rapidly after completing front-line
chemotherapy (“refractory relapse”).6 Although the major fac-
tors underlying resistance to chemotherapy remain undefined,
numerous factors may contribute.7,8
We postulated that dose-response curve (DRC) shape
(log % cell survival versus dose) would reflect major resis-
tance mechanisms limiting drug efficacy (Figure 1).8,9 By this
hypothesis, excess of a resistance factor such as an efflux
pump and DNA repair (“active resistance”) would give a
DRC shoulder, analogous to competitive inhibition of drug
effect. In this situation, the DRC slope would steepen after
resistance factors had been overwhelmed by higher doses.
One would not expect DRC flattening, because one would not
expect the resistance mechanism to be ineffective at low
doses and then become increasingly effective at higher doses.
Mutation or alteration of a factor such as a target or drug
uptake mechanism (“nonsaturable passive resistance”) would
give reduced DRC slope, pharmacodynamically analogous to
decreased affinity of a drug for its receptor. The rationale for
the explanation of nonsaturable passive resistance is that one
would not expect the efficacy of a resistance factor to increase
proportionately to the effect of an increasing drug dose.
Saturation or deficiency of something required for cell killing
(e.g., a drug uptake system or cells in a sensitive phase of the
cell cycle) (“saturable passive resistance”) would give DRC
flattening at higher doses, analogous to noncompetitive inhi-
bition of drug effect. In non-small cell lung cancer (NSCLC),
we found that DRCs flatten at higher doses for all regimens
assessed, suggesting that in NSCLC efficacy is limited by
saturation or deficiency of factors required for drug effic-
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acy.10 Herein, we used DRC assessments in SCLC as a basis
for generating hypotheses regarding resistance mechanisms
limiting drug efficacy in extensive disease.
METHODS
To be eligible for inclusion, a study had to report
response rate using World Health Organization11 or
RECIST12 criteria for front-line chemotherapy in ED
SCLC. Studies were not included if they used alternating
or cross-over designs, used radiotherapy, did not differen-
tiate between ED and LD SCLC or between SCLC and
NSCLC (if both LD and ED or both SCLC and NSCLC
were included in the study), were restricted to tumor in a
specific anatomic location (e.g., brain), or were testing
primarily maintenance therapy or new drug administration
methods or schedules. Using PUBMED and manual
searches, we identified 46 studies (reporting 62 drug com-
binations) published between 1985 and 2005 that met all
inclusion criteria (Table 1).13–58
We used response rate to roughly estimate mean %
tumor cell kill for each trial. We assumed tumor cell kill was
proportional to reduction in tumor volume, recognizing that
several factors would reduce estimate accuracy, including
tumor regrowth between cycles, residual necrotic or stromal
cells, tumor measurement inaccuracies, tumor shape irregu-
larity, etc., and recognizing that the relationship between
response rate and % tumor cell kill has to our knowledge
never actually been proven in either preclinical or clinical
investigations. For complete responses (CR), we assumed
more than 99% tumor cell kill. For a partial response, a tumor
diameter decreases to less than 0.7 of the original diameter
(with a decrease in the product of widest perpendicular
diameters to 0.7  0.7  0.49 of the original). This in turn
translates roughly into a reduction in tumor volume to
0.7  0.7  0.7  0.343 of the original volume, such that
the tumor has to have lost more than 65.7% of its original
volume to be classified as a partial response. Hence, for the
purposes of this study, we assumed that the average patient
with a partial response would have an 83% reduction in tumor
volume [(100  65.7)/2] and an average 83% cell kill.
Because stable disease (SD) represents a 30% reduction in
tumor diameter up to a 12 to 20% increase in tumor diameter
(depending on whether World Health Organization or RECIST
criteria are used), we assumed that the average SD patient had
a 13% cell kill. For patients with progressive disease (PD),
we assumed a 0% cell kill, recognizing that this would
substantially underestimate cell kill in some patients, such as
those who had initial tumor shrinkage followed by rapid
regrowth. Mean % tumor cell kill for the average patient in an
individual study was calculated as 100 ([no. CR 0.99]
[no. PR 0.83] [no. SD 0.13])/number of patients in the
study.
Nonlinear meta-regression analysis (with each study
weighted by number of patients) was then performed using
SAS to model the relationship between mean % cell survival
and dose intensity. Based on observations in our earlier
studies in NSCLC,10 we hypothesized that in SCLC we would
initially see a downward slope on the survival curve with
FIGURE 1. We postulated that
dose-response curve shape would
reflect whether resistance was due
to deficiency or saturation of a fac-
tor required for drug effect (which
would result in flattening of the
dose-response curve at higher
doses, “saturable passive resis-
tance,” analogous to noncompeti-
tive inhibition of drug effect), due
to mutation, etc., resulting in de-
creased affinity of a drug for an up-
take system, target, etc. (which
would give decreased curve slope,
“nonsaturable passive resistance”),
or due to excess of a resistance fac-
tor (which would give a shoulder on
the dose-response curve if log effect
is plotted against linear dose, “ac-
tive resistance,” analogous to com-
petitive inhibition of drug effect).
Reprinted with permission from Crit
Rev Oncol Hematol.8
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increasing dose, followed by a flattening of the curve at
highest doses. To test this hypothesis, we assessed whether
data could be fit using a weighted nonlinear regression
function characterized by the following mean function:
% Tumor Cell Survival
 ((1) exp(  dose-intensity)),
subject to the restrictions 0    1, 5    0, 0   
100, where the  parameter measures the relationship be-
tween dose and cell survival,  is the point at which cell
survival plateaus, and  is a scaling factor to permit scaling
from 0 to 100%. Note that the  parameter characterizes the
effect of dose on % cell survival and is set to be negative to
ensure that % cell survival decreases with dose; the  param-
eter, as stated above, characterizes a level at which % cell
survival plateaus and below which % cell survival does not
fall. The plateau point characterized by  can be thought of as
analogous to the cure rate fraction in some survival models.
Weighted linear regression analysis was used where data
could not be fit to this nonlinear model. The criteria for using
weighted linear regression models in place of weighted non-
linear models were when the weighted linear regression
model resulted in lower (i.e., better) Akaike information
criterion than the weighted nonlinear model. For carboplatin
trials reporting dose as mg/m2, AUC dose was estimated. For
oral etoposide, 50% bioavailability was assumed.59
Analyses were done over the entire dose range avail-
able for each drug and were repeated after eliminating lower
doses at or below the lower limit of those commonly used.
RESULTS
Sufficient data were available to permit analyses for
cisplatin, carboplatin, cyclophosphamide, ifosfamide, etopo-
side, epirubicin, and paclitaxel (Table 2), whereas data were
insufficient for analysis of other agents. Figure 2 shows the
curves over the entire dose range assessed for each drug. Data
were fit using a weighted nonlinear meta-regression model
for cisplatin and cyclophosphamide, whereas weighted linear
regression models are presented for the other agents, because
the  parameter could not be fit by the nonlinear regression
model. The parameter estimates and SEs for the models when
all data are used for modeling are given in Table 3. In
addition, for each model, we present the fitted models in
Figures 2 and 3. For each of cisplatin, cyclophosphamide,
ifosfamide, etoposide, and paclitaxel, there was a downward
slope on the DRC, with increasing cell kill with increasing
dose intensity, although this association between dose inten-
sity and cell kill did not achieve statistical significance. When
lowest drug doses were omitted (Figure 3), data for each of
cisplatin, carboplatin, cyclophosphamide, and ifosfamide
could be fit by the weighted nonlinear meta-regression model,
and there was a downward curve slope for all seven agents,
although again, statistical significance was not achieved.
Similar results were obtained using nonweighted anal-
yses and using log % cell survival rather than % cell survival
(data not shown). Irrespective of drug doses and combina-
tions used, mean cell kill generally did not exceed 90%
(Figures 2 and 3). Although several studies achieved this cell
kill, none substantially exceeded it no matter how many drugs
were used and no matter what doses per cycle or total
cumulative doses were used.
TABLE 2. Number of Patients in Evaluable Studies
Drug
No. of Patients
Total No. of
Patients
(No. of Studies)
Study Size
(Median)
Study Size
(Range)
Cisplatin 2198 (30) 58 15–283
Cyclophosphamide 294 (8) 32 17–65
Carboplatin 605 (11) 43 28–156
Ifosfamide 588 (11) 54 16–87
Etoposide 2831 (40) 51 16–283
Epirubicin 680 (11) 65 30–78
Paclitaxel 575 (8) 42 34–283
TABLE 1. Regimens Included
Regimen
No. of
Studies
Cisplatin  etoposide 9
Ifosfamide 3
Paclitaxel 2
Irinotecan 2
Topotecan 1
Doxorubicin  vincristine 2
Doxorubicin  cyclophosphamide 1
Epirubicin  cyclophosphamide 2
Epirubicin  ifosfamide 1
Cisplatin  epirubicin 1
Cisplatin  irinotecan 2
Cisplatin  paclitaxel  topotecan 1
Carboplatin  etoposide 3
Vincristine 1
Epirubicin 2
Epirubicin  ifosfamide 1
Carboplatin  teniposide 1
Carboplatin  vinorelbine 2
Carboplatin  paclitaxel 1
Ifosfamide 1
Cyclophosphamide  epirubicin 1
Cyclophosphamide  etoposide 2
Etoposide 1
Etoposide  ifosfamide 1
Etoposide  paclitaxel 1
Etoposide  vincristine 1
Docetaxel 1
Docetaxel  gemcitabine 2
Doxorubicin  etoposide  ifosfamide 1
Epirubicin 1
Epirubicin  ifosfamide  vindesine 3
Paclitaxel 2
Topotecan 1
Vinorelbine 1
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DISCUSSION
Despite often initially responding well to chemother-
apy, ED SCLC remains incurable. The reasons for this
incurability are unknown. Several resistance mechanisms
have been described in SCLC cell lines and xenografts,8,60
but it is unclear which of these are important clinically.
Although this study was limited by a relatively small number
of evaluable studies and by our inability to correct for the
contribution of concurrent agents in drug combination stud-
ies, the lack of a statistically significant association between
dose intensity of any agent and estimated cell kill would
argue against a steep DRC for any of the agents assessed.
This is in keeping with our observation that there seems to be
a maximum mean cell kill of around 90% across all ED
SCLC studies, irrespective of drug type, number of drugs
used, drug doses per cycle, dose intensity, total cumulative
drug dose administered, treatment schedule, or cell cycle
specificity of the agents used. This apparent maximum cell
kill of around 90% irrespective of drug used would suggest
that DRCs for all agents flatten at higher drug doses, and that
there is no combination, dose, or schedule of currently avail-
able agents that would be capable of curing ED SCLC. Even
very high chemotherapy doses failed to improve outcome.
This is similar to our observation of DRC flattening at higher
doses in NSCLC10 and is in keeping with the inability of even
very high drug doses with bone marrow transplantation to
cure any metastatic epithelial malignancies.61 Overall, the
observations in this study are in keeping with our earlier
conclusion10 that there could possibly be a common factor
that limits curability of all metastatic epithelial malignancies.
If interpreted according to our hypothesis on the link between
DRC shape and resistance mechanisms,9 this DRC flattening
would suggest that the major problem is one of deficiency or
saturation of a factor required for drug efficacy, rather than
incurability being due to excess of resistance factors such as
efflux pumps or DNA repair pathways. By our hypothesis,9
“active” resistance factors such as efflux pumps or DNA
repair pathways would be most important at low drug doses
FIGURE 2. Weighted nonlinear meta-regression analysis (where the  parameter measures the relationship between dose
and cell survival) or weighted linear regression analysis (where the  parameter measures the relationship between dose and
cell survival) over the entire dose range assessed. Data for each of cisplatin (n  30,   0.02) and cyclophosphamide (n 
8,   0.01) could be fitted to the nonlinear regression model, whereas data for each of etoposide (n  40,   0.01),
carboplatin (n  11,   0.14), epirubicin (n  11,   0.25), paclitaxel (n  8,   0.11), and ifosfamide (n  11,  
0.01) could not be fitted to the nonlinear regression model and were instead assessed by linear regression analysis.
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but should be surmountable by increasing drug doses. Al-
though there was a downward slope on many of the DRCs,
this was not statistically significant for any agent, and the
observation of a maximum mean cell kill that was consistent
across all agents suggests that there is an upper limit to the
cell kill achievable by augmenting drug doses.
One possible explanation of the DRC flattening would
be the presence of quiescent cells in the tumor that survive the
first cycle of chemotherapy, irrespective of drug dose. Qui-
escent cells generally have increased resistance to ther-
apy,62–64 and various preclinical observations support a link
between quiescence and resistance. For example, resistance
may be accompanied by decreased tumorigenic capacity,65 a
decrease in uptake across cell membranes of a broad range of
factors and drugs,66 downregulation of expression of various
membrane receptors and transporters,66 decreased amount
and altered localization of a variety of membrane proteins,65
faulty or decreased endocytosis,66,67 reversible senes-
cence,68,69 autophagy,70 or appearance of nondividing
multinucleated cells that may later resume cell cycling.71
If quiescent cells did survive the first cycle of chemo-
therapy irrespective of dose (thereby flattening DRCs), these
surviving quiescent cells might maintain their quiescent phe-
notype for a prolonged period of time after drug exposure but
might ultimately start cycling again, as has been described for
quiescent cells in some preclinical lung cancer systems.68,69,71
The fact that occasional late relapses are seen in patients with
SCLC72–75 is in keeping with SCLC cells being capable of
reversible quiescence. If resistance was due to quiescence,
then the tumor cells might potentially be sensitive again when
they ultimately resumed cycling. Such a pattern of prolonged
quiescence followed by drug-sensitive tumor regrowth would
be in keeping with the observation in SCLC that patients who
do not require reinitiation of chemotherapy until more than 3
months after their prior therapy may again be sensitive to
chemotherapy when they ultimately do suffer tumor regrowth
(the “sensitive relapse” phenotype6). In addition, with in-
creasing time after exposure of cancers to prior therapy, there
can be reduction in DNA hypermethylation and re-expression
of transporters and other factors that have been downregu-
lated as a consequence of exposure to chemotherapy and that
may be required for drug efficacy.76
Conversely, chemotherapy exposure can also in some
cases result in recruitment of quiescent cells into active
proliferation,77 and there can be rapid regrowth of tumors
between chemotherapy cycles, with increasingly rapid re-
population and resistance due to this “accelerated repopula-
tion.”78 Exposure of tumor cells to chemotherapy can also
result in upregulation of expression of resistance factors.8,79,80
Tumors that regrow during chemotherapy or shortly after
completion of chemotherapy are generally resistant to further
chemotherapy,6 and this could potentially be attributable to
the combination of accelerated repopulation78 and upregula-
tion of expression of resistance factors.8,79,80 In this instance,
increasing drug doses might hypothetically somewhat im-
prove therapy efficacy, but residual resistant quiescent cells
would still ultimately limit outcome and flatten DRCs at
highest doses.
Although the above could explain both DRC flattening
and relapse patterns, it is stressed that our proposed explana-
tion is highly speculative. In both preclinical and clinical
studies, numerous resistance mechanisms have been noted in
SCLC,8,60 and it remains unknown which ones are most
important clinically. The field would benefit from carefully
done translational studies (with tumor biopsies before therapy
initiation and again at the time of maximum response and at
the time of relapse) to assess how tumor cell growth charac-
teristics, resistance factors, and factors required for therapy
efficacy (e.g., drug obligate targets, drug transporters, drug
activators, and proapoptotic factors) change over the course
of therapy. If the initial presence of quiescent cells did prove
to be central to the ultimate failure of therapy, then it would
be particularly important to define potentially exploitable
targets in these quiescent cells.
TABLE 3. Model Estimates, SEs, and 95% Confidence Intervals
Treatment Model Parameter
Parameter
Estimate (SE)
Lower 95%
Limit
Upper 95%
Limit
Cisplatin Nonlinear  0.0233 (0.02) 0.0624 0.0159
 0.00 (0.00) 0.000 0.000
 63.36 (29.65) 2.63 124.10
Cyclophosphamide Nonlinear  0.0052 (0.003) 0.011 0.00084
 0.0061 (0.200) 0.484 0.4958
 100.00 (0.00) 100.000 100.000
Carboplatin Linear Intercept 27.179 (11.730) 0.645 53.714
Slope 0.137 (7.527) 16.889 17.164
Ifosfamide Linear Intercept 43.636 (12.536) 15.277 71.994
Slope 0.006 (0.006) 0.020 0.008
Etoposide Linear Intercept 35.671 (7.311) 20.871 50.471
Slope 0.014 (0.056) 0.128 0.100
Epirubicin Linear Intercept 23.584 (10.728) 0.685 46.754
Slope 0.248 (0.334) 0.507 1.003
Paclitaxel Linear Intercept 41.072 (30.349) 33.189 115.332
Slope 0.105 (0.499) 1.326 1.115
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The main purpose of this assessment was not to
determine whether or not there is a benefit from adminis-
tering higher doses of chemotherapy but rather to assess
DRC shape, and the relatively small number of evaluable
studies meant that statistical power was low. We did
observe a downward slope in the DRCs for five of the
seven agents over all dose intensities, and a downward
slope was also seen for the two remaining drugs if the
relatively flat early low-dose curve portion was omitted,
but as noted above, the association between dose intensity
and efficacy did not achieve statistical significance for any
of the agents assessed. Recent reviews have also concluded
that there is no proven benefit of higher dose intensity or
dose density in SCLC.1,2,4,5,81 Nevertheless, available data
suggest that it may be premature to conclude that dose is
largely unimportant. In randomized trials, significant im-
provements in median survival,37,82–89 % 2-year survi-
val,37,82,83,85–88 relapse-free survival,90 complete response
rates84,85,90–92 or overall response rates,52,83,87,89,93–95 or a
statistically nonsignificant trend toward higher response
rates52,82,84,86,93,96 or longer survival90,97 have been re-
ported with a variety of higher dose approaches or with
addition of more agents to a therapy regimen. Only a
minority of randomized trials have failed to show even a
trend toward improvement in either survival or response
with higher dose approaches or with increase in the num-
ber of agents used.45,48,98–103 Hence, despite the fact that
even high drug doses are incapable of curing ED SCLC, it
remains possible that higher drug doses may at least
modestly improve palliation and short-term tumor
control.
In summary, while maintaining relatively high doses
of chemotherapy may possibly have a modestly positive
impact in ED SCLC, DRC flattening at higher doses may
preclude cure with currently available agents. The appar-
ent DRC flattening would suggest that incurability of ED
SCLC is due to deficiency or saturation of a factor or
factors required for drug efficacy, and further progress will
depend on our defining new therapeutic methods specifi-
cally targeting these resistant cells.
FIGURE 3. Weighted nonlinear meta-regression analysis (where the  parameter measures the relationship between dose
and cell survival) or weighted linear regression analysis (where the  parameter measures the relationship between dose and
cell survival) over higher doses (with elimination of data for doses of etoposide 100, cisplatin 20, epirubicin 20, cyclo-
phosphamide 200, paclitaxel 35, or ifosfamide 1250 mg/m2/wk or carboplatin  AUC 1.25/wk). Data for each of cisplatin
(n  22,   0.02), carboplatin (n  6,   0.39), cyclophosphamide (n  3,   0.01), and ifosfamide (n  9,  
0.0004) could be fitted to the nonlinear regression model, whereas data for each of etoposide (n  20,   0.09), epirubicin
(n  7,   0.48), and paclitaxel (n  8,   0.11) could not be fitted to the nonlinear regression model and were instead as-
sessed by linear regression analysis.
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